Quick context
Retatrutide
正在就体重、代谢以及心血管和肾脏结局开展临床研究。
Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.
Back to all 64 profiles
Clinical research临床研究中WADA
Community protocol · Retatrutide
Retatrutide: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: LY3437943 · GLP-1/GIP/glucagon
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Clinical research
Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.
Amount status
Trials use protocol-bound amounts and escalation; this does not create a safe community dose.
Profile evidence level: clinical.
Timing
Timing is set by each trial protocol and may differ substantially between studies.
No individual recommendation.
Cycle/duration
Duration is study-specific and ends according to protocol; long-term safety may remain unknown.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
复配计算器
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
复配计算器
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
GIP, GLP-1 and glucagon receptor agonist
Retatrutide is classified as “GIP, GLP-1 and glucagon receptor agonist”. 正在就体重、代谢以及心血管和肾脏结局开展临床研究。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
三重受体激活
这项研究关注同时激活三种代谢受体是否比激活两种或一种带来额外益处,例如在能量消耗和脂肪分解方面。通常测量体重变化、肝脂肪水平和卡路里消耗。
体重与代谢
研究人员在研究过程中追踪体重、身体成分以及血糖或胆固醇等代谢指标的变化。这类似于连续数月跟踪一个人的体重和化验值,以观察总体趋势而非每日波动。
肝脏与心肾结局
这项研究关注对肝脂肪、心脏功能和肾脏指标的影响,这些器官通过共同的代谢和血流通路紧密相连。研究通常随时间测量肝脂肪影像、血压和肾功能检测结果。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
体重管理论坛
在这些论坛中,用户比较不同产品之间自己的体重变化、副作用以及感知到的食欲变化。经常会分享前后对比照片和个人时间线。这类轶事和商家营销宣传并不是科学的疗效证明。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
组合与混合物讨论
用户分享自行组合的多种肽方案,并比较感知到的效果,而具体的组合方式往往从未经过研究。这类组合建议属于个人意见,而非经过验证的方案。
Adverse effects and risk boundaries
- 根据靶点，可能出现胃肠道反应、脱水以及血糖或食欲变化；肠促胰素类药物还可能涉及胆囊、胰腺和视网膜病变警示。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 妊娠、严重胃排空障碍以及相关胰腺、胆囊、肾脏或内分泌疾病均需专业评估；具体说明书还可能列出其他禁忌。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 根据物质和适应证，可评估体重、血压、水合状态、血糖/HbA1c、肝肾指标及合并用药；其他检查由症状决定。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
临床试验中
该药物仍处于临床测试阶段,尚未获批成为药品。
Published evidence
该物质目前正在结构化的人体临床试验中进行研究,尚未获得普遍批准。
瑞他鲁肽是一种三重受体激动剂,不同于单一或双重受体的GLP-1药物。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
临床研究中
处于临床开发阶段，尚不是获批药物。
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceClinicalTrials.gov: NCT06383390
- Primary/technical sourceJastreboff et al. — Retatrutide phase 2 trial
- Primary/technical sourceWADA — 2026 Prohibited List
- Community referenceRetatrutide — Peptide Dosing Protocols